Guardant Health (GH) Trading Down 1.5% Following Weak Earnings
Guardant Health Inc (NASDAQ:GH) shares traded down 1.5% during mid-day trading on Tuesday following a dissappointing earnings announcement. The company traded as low as $32.15 and last traded at $33.10. 11,870 shares were traded during mid-day trading, a decline of 97% from the average session volume of 359,144 shares. The stock had previously closed at $33.62.
The company reported ($1.94) EPS for the quarter, missing the consensus estimate of ($0.29) by ($1.65). The company had revenue of $21.70 million during the quarter, compared to the consensus estimate of $17.44 million. The firm’s quarterly revenue was up 95.5% compared to the same quarter last year.
Several equities research analysts recently commented on the company. JPMorgan Chase & Co. assumed coverage on Guardant Health in a report on Monday, October 29th. They issued an “overweight” rating and a $42.00 price objective for the company. Bank of America assumed coverage on Guardant Health in a report on Monday, October 29th. They issued a “neutral” rating and a $37.00 price objective for the company. Cowen assumed coverage on Guardant Health in a report on Monday, October 29th. They issued an “outperform” rating for the company. William Blair assumed coverage on Guardant Health in a report on Monday, October 29th. They issued an “outperform” rating for the company. Finally, Leerink Swann reiterated an “outperform” rating on shares of Guardant Health in a report on Monday, October 29th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Guardant Health presently has a consensus rating of “Buy” and an average price target of $39.50.
ILLEGAL ACTIVITY NOTICE: “Guardant Health (GH) Trading Down 1.5% Following Weak Earnings” was posted by Daily Political and is owned by of Daily Political. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at https://www.dailypolitical.com/2018/11/20/guardant-health-gh-trading-down-1-5-following-weak-earnings.html.
Guardant Health, Inc, a precision oncology company, provides non-invasive cancer diagnostics. It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA (ctDNA); and GuardantOMNI, a broader panel measuring various genes from ctDNA.
Further Reading: What is a Stop Order?
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.